Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Yian Du"'
Autor:
Pengfei Yu, Ping Chen, Min Wu, Guangyu Ding, Hua Bao, Yian Du, Zhiyuan Xu, Litao Yang, Jingquan Fang, Xingmao Huang, Qian Lai, Jia Wei, Junrong Yan, Shanshan Yang, Peng He, Xue Wu, Yang Shao, Dan Su, Xiangdong Cheng
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-14 (2024)
Abstract Background Gastric cancer is the fifth most common cancer type. Most patients are diagnosed at advanced stages with poor prognosis. A non-invasive assay for the detection of early-stage gastric cancer is highly desirable for reducing associa
Externí odkaz:
https://doaj.org/article/adb53d5c60b84f4ead5c7b399a2e5228
Autor:
Pengfei Yu, Can Hu, Guangyu Ding, Xiaoliang Shi, Jingli Xu, Yang Cao, Xiangliu Chen, Wei Wu, Qi Xu, Jingquan Fang, Xingmao Huang, Shaohua Yuan, Hui Chen, Zhizheng Wang, Ling Huang, Fei Pang, Yian Du, Xiangdong Cheng
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Ovarian metastasis is one of the major causes of treatment failure in patients with gastric cancer (GC). However, the genomic characteristics of ovarian metastasis in GC remain poorly understood. In this study, we enroll 74 GC patients with
Externí odkaz:
https://doaj.org/article/acd7816f5cb14672aa1c601f0fd5d0b1
Autor:
Jingquan Fang, Xingmao Huang, Xiangliu Chen, Qi Xu, Tengjiao Chai, Ling Huang, Han Chen, Hang Chen, Zeyao Ye, Yian Du, Pengfei Yu
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17126-17138 (2023)
Abstract Background Ovarian metastasis from gastric cancer (GC) is characterized by aggressive biological behavior and poor outcome. Currently, there is no standard treatment mode for such patients. Thus, we evaluated the efficacy of conversion thera
Externí odkaz:
https://doaj.org/article/a85e3f21427448d392affeea8c35aef3
Autor:
Jinwen Shen, Xiu Zhu, Yian Du, Yuan Zhu, Pengfei Yu, Litao Yang, Zhiyuan Xu, Ling Huang, Yunli Zhang, Yanqiang Zhang, Luying Liu, Xiangdong Cheng
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Survival benefit of adjuvant radiotherapy for locally advanced gastric cancer following gastrectomy plus D2 lymphadenectomy has always been controversial. Esophagogastric junction (EGJ) adenocarcinoma, which is usually classified
Externí odkaz:
https://doaj.org/article/7ec8d549b800475b97cb74ba1cfc82b1
Autor:
Xiangdong Cheng, Dan Wu, Nong Xu, Luchuan Chen, Zhilong Yan, Ping Chen, Lei Zhou, Jianfa Yu, Jiuwei Cui, Wei Li, Chang Wang, Wenming Feng, Yunhai Wei, Pengfei Yu, Yian Du, Jieer Ying, Zhiyuan Xu, Litao Yang, Yunli Zhang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Surgery is the only treatment option for operable gastric cancer. The CLASSIC and ACTS-GC studies showed that the 5-year overall survival (OS) of patients with stage III gastric cancer undergoing D2 gastrectomy is still very low.
Externí odkaz:
https://doaj.org/article/330179c7f4ff4d3b97e31f31237cdad5
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background There is no currently available treatment for peritoneal metastasis of gastric cancer. This phase II study aimed to evaluate the efficacy and safety of neoadjuvant systemic chemotherapy and hyperthermic intraperitoneal chemotherap
Externí odkaz:
https://doaj.org/article/e9fe14e271564f979add2b0d1749a723
Autor:
Deqiang Wang, Xiaofeng Chen, Yian Du, Xiaoqin Li, Leqian Ying, Yi Lu, Bo Shen, Xuan Gao, Xin Yi, Xuefeng Xia, Xinbing Sui, Yongqian Shu
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundHER2 is one of the most extensively studied oncogenes in solid tumors. However, the association between tumor microenvironment (TME) and HER2 mutation remains elusive, and there are no specific therapies for HER2-mutated tumors. Immune chec
Externí odkaz:
https://doaj.org/article/67da4aa7e25044d7bc32202561005d42
Publikováno v:
World Journal of Surgical Oncology, Vol 17, Iss 1, Pp 1-6 (2019)
Abstract Background The optimal extent of lymph node (LN) dissection for advanced distal gastric cancer remains controversial. The present study compared the safety and efficacy of extended LN dissection (D2 plus) with standard D2 radical surgery for
Externí odkaz:
https://doaj.org/article/c28e48dde66946398e652053ab942afb
Autor:
Zhiyuan Xu, Can Hu, Jianfa Yu, Yian Du, Ping Hu, Guofa Yu, Conggang Hu, Yu Zhang, Wei Mao, Shanqi Chen, Xiangdong Cheng
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Objective: Conversion therapy (surgical resection after chemotherapy) is a promising option for unresectable gastric cancer (GC) patients. Addition of anti-angiogenesis drug improves response to chemotherapy. Hence, this study explored the feasibilit
Externí odkaz:
https://doaj.org/article/164b55f948a44e0c9d7f0bb9fff4e64c
Autor:
Yanqiang, Zhang, Xiaoqing, Xu, Can, Hu, Yian, Du, Guangyu, Ding, Jiahui, Chen, Xiu, Zhu, Zhiyuan, Xu, Qing, Wei
Publikováno v:
Translational Cancer Research. 11:2145-2156
Conversion surgery is a treatment that aims for R0 resection of primary advanced gastric cancers (GCs) that have responded well to systemic chemotherapy. We investigated the role of conversion therapy in initially unresectable metastatic cancer with